Tech Company Financing Transactions
Ryvu Therapeutics Funding Round
Ryvu Therapeutics closed a $8.7 million funding round on 3/6/2024. Investors included European Investment Bank.
Transaction Overview
Company Name
Announced On
3/6/2024
Transaction Type
Venture Equity
Amount
$8,700,000
Round
Undisclosed
Investors
Proceeds Purpose
The EIB's financial support will help Ryvu finance its development pipeline of new cancer treatments, from discovery to clinical trials. Ultimately, Ryvu aims to address the clinical limitations of current treatments in oncology and provide patients with access to innovative therapies for hematologic and solid tumors.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2
Kraków, 30-394
Poland
Kraków, 30-394
Poland
Phone
Website
Email Address
Overview
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. Ryvu Therapeutics was founded in 2007 and currently we employee approximately 260 employees, including 90 Ph.Ds. Ryvu was previously known as Selvita, until renamed to Ryvu Therapeutics after spin out of the services segment.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Pawel Przewiezlikowski
Chief Medical Officer
Hendrik Nogai
Chief Operating Officer
Kamil Sitarz
Chief Scientific Officer
Krzysztof Brzozka
VP - Bus. Development
Vatnak Vat-Ho
Browse more venture capital transactions:
Prev: 3/6/2024: Betr venture capital transaction
Next: 3/6/2024: Bene Bono venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs